Angiopoietin 2, VEGF dual antagonists
The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).
1. A chimeric molecule, which comprises
an amino acid sequence at least 99% identical or 100% identical as one selected from the group consisting of SEQ ID NOS: 31, 32, and 34.
2. A chimeric molecule
which comprises an amino acid sequence at least 99% identical or 100% identical as one selected from SEQ ID NO: 37, 39, 41, 43, 45, 47, 49, 51, and 53.
3. A pharmaceutical composition comprising the chimeric molecule of claim 1 and a pharmaceutically acceptable excipient.
4. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition contains one or more acceptable carriers.
5. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is in the form of a lyophilized formulation or an aqueous solution.
6. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition includes one or more of carriers, an excipient, a diluent, a suitable binder, a lubricant, a suspension agent, a coating agent or a solubilizing agent.
7. A pharmaceutical composition comprising the chimeric molecule of claim 2 and a pharmaceutically acceptable excipient.